Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1993 May;67(5):1122–1125. doi: 10.1038/bjc.1993.206

First experience with FGF-3 (INT-2) amplification in women with epithelial ovarian cancer.

A Rosen 1, P Sevelda 1, M Klein 1, K Dobianer 1, C Hruza 1, K Czerwenka 1, H Hanak 1, N Vavra 1, H Salzer 1, S Leodolter 1, et al.
PMCID: PMC1968420  PMID: 8494710

Abstract

Estimation of FGF-3 oncogene amplification in DNA samples extracted from paraffin embedded sections of 136 ovarian cancer samples was carried out by a quantitative PCR method. The aim of this study was to elucidate a possible association of FGF-3 copy numbers with established prognostic factors such as age, histology, FIGO stage, grading, postoperative residual tumour mass, ascites, hormone receptor content and preoperative CA 125 serum levels. In addition, correlation of FGF-3 amplification with overall survival of the patients was assessed. There was a borderline positive correlation between preoperative CA 125 serum levels and the degree of amplification of the FGF-3 gene (P = 0.06). A statistically significant association of FIGO-stage with FGF-3 copy number could be found (P = 0.008). No correlation between FGF-3 amplification and overall survival was noted. The data combine to suggest that FGF-3 is an indicator of aggressiveness of ovarian cancer.

Full text

PDF
1122

Images in this article

1123Figure 1
on p.1123

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adnane J., Gaudray P., Simon M. P., Simony-Lafontaine J., Jeanteur P., Theillet C. Proto-oncogene amplification and human breast tumor phenotype. Oncogene. 1989 Nov;4(11):1389–1395. [PubMed] [Google Scholar]
  2. Bast R. C., Jr, Klug T. L., St John E., Jenison E., Niloff J. M., Lazarus H., Berkowitz R. S., Leavitt T., Griffiths C. T., Parker L. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med. 1983 Oct 13;309(15):883–887. doi: 10.1056/NEJM198310133091503. [DOI] [PubMed] [Google Scholar]
  3. Casey G., Smith R., McGillivray D., Peters G., Dickson C. Characterization and chromosome assignment of the human homolog of int-2, a potential proto-oncogene. Mol Cell Biol. 1986 Feb;6(2):502–510. doi: 10.1128/mcb.6.2.502. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Day T. G., Jr, Gallager H. S., Rutledge F. N. Epithelial carcinoma of the ovary:prognostic importance of histologic grade. Natl Cancer Inst Monogr. 1975 Oct;42:15–21. [PubMed] [Google Scholar]
  5. Dickson C., Peters G. Potential oncogene product related to growth factors. 1987 Apr 30-May 6Nature. 326(6116):833–833. doi: 10.1038/326833a0. [DOI] [PubMed] [Google Scholar]
  6. Dickson C., Smith R., Brookes S., Peters G. Tumorigenesis by mouse mammary tumor virus: proviral activation of a cellular gene in the common integration region int-2. Cell. 1984 Jun;37(2):529–536. doi: 10.1016/0092-8674(84)90383-0. [DOI] [PubMed] [Google Scholar]
  7. Eisner J. M., Casey B. J. Malpractice, informed consent, and the use of low osmolality contrast media. Conn Med. 1988 Feb;52(2):87–91. [PubMed] [Google Scholar]
  8. Grill H. J., Manz B., Belovsky O., Pollow K. Criteria for the establishment of a double-labeling assay for simultaneous determination of estrogen and progesterone receptors. Oncology. 1984;41(1):25–32. doi: 10.1159/000225785. [DOI] [PubMed] [Google Scholar]
  9. Lidereau R., Callahan R., Dickson C., Peters G., Escot C., Ali I. U. Amplification of the int-2 gene in primary human breast tumors. Oncogene Res. 1988 Feb;2(3):285–291. [PubMed] [Google Scholar]
  10. Makar A. P., Kristensen G. B., Kaern J., Børmer O. P., Abeler V. M., Tropé C. G. Prognostic value of pre- and postoperative serum CA 125 levels in ovarian cancer: new aspects and multivariate analysis. Obstet Gynecol. 1992 Jun;79(6):1002–1010. [PubMed] [Google Scholar]
  11. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966 Mar;50(3):163–170. [PubMed] [Google Scholar]
  12. Moore R., Casey G., Brookes S., Dixon M., Peters G., Dickson C. Sequence, topography and protein coding potential of mouse int-2: a putative oncogene activated by mouse mammary tumour virus. EMBO J. 1986 May;5(5):919–924. doi: 10.1002/j.1460-2075.1986.tb04304.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Peters G., Brookes S., Smith R., Dickson C. Tumorigenesis by mouse mammary tumor virus: evidence for a common region for provirus integration in mammary tumors. Cell. 1983 Jun;33(2):369–377. doi: 10.1016/0092-8674(83)90418-x. [DOI] [PubMed] [Google Scholar]
  14. Peters G., Kozak C., Dickson C. Mouse mammary tumor virus integration regions int-1 and int-2 map on different mouse chromosomes. Mol Cell Biol. 1984 Feb;4(2):375–378. doi: 10.1128/mcb.4.2.375. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Rosen A., Sevelda P., Klein M., Spona J., Beck A. A CA125 score as a prognostic index in patients with ovarian cancer. Arch Gynecol Obstet. 1990;247(3):125–129. doi: 10.1007/BF02390860. [DOI] [PubMed] [Google Scholar]
  16. Rychlik W., Rhoads R. E. A computer program for choosing optimal oligonucleotides for filter hybridization, sequencing and in vitro amplification of DNA. Nucleic Acids Res. 1989 Nov 11;17(21):8543–8551. doi: 10.1093/nar/17.21.8543. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Saiki R. K., Gelfand D. H., Stoffel S., Scharf S. J., Higuchi R., Horn G. T., Mullis K. B., Erlich H. A. Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase. Science. 1988 Jan 29;239(4839):487–491. doi: 10.1126/science.2448875. [DOI] [PubMed] [Google Scholar]
  18. Schuuring E., Verhoeven E., Mooi W. J., Michalides R. J. Identification and cloning of two overexpressed genes, U21B31/PRAD1 and EMS1, within the amplified chromosome 11q13 region in human carcinomas. Oncogene. 1992 Feb;7(2):355–361. [PubMed] [Google Scholar]
  19. Sevelda P., Rosen A., Denison U., Barrada M., Spona J., Salzer H. Is CA-125 monitoring useful in patients with epithelial ovarian carcinoma and preoperative negative CA-125 serum levels? Gynecol Oncol. 1991 Nov;43(2):154–158. doi: 10.1016/0090-8258(91)90063-b. [DOI] [PubMed] [Google Scholar]
  20. Sevelda P., Schemper M., Spona J. CA 125 as an independent prognostic factor for survival in patients with epithelial ovarian cancer. Am J Obstet Gynecol. 1989 Nov;161(5):1213–1216. doi: 10.1016/0002-9378(89)90668-6. [DOI] [PubMed] [Google Scholar]
  21. Zhou D. J., Ahuja H., Cline M. J. Proto-oncogene abnormalities in human breast cancer: c-ERBB-2 amplification does not correlate with recurrence of disease. Oncogene. 1989 Jan;4(1):105–108. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES